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Abstract 
 
Background: HIV accelerates the development of cervical cancer by up to15 years. South 
Africa is currently in the midst of an HIV epidemic. With limited facilities for colposcopy it is 
vital to identify risk factors within the HIV positive population resulting in positive margins 
after Large Loop Excision of the Transformation Zone (LLETZ) and persistence of 
cytological abnormalities on follow-up Pap smears. 
 
Objective: The primary objective was to determine the patient risk factors, pre and during 
colposcopy and LLETZ biopsy, which resulted in the histological involvement of margins of 
the LLETZ biopsy and persistent cervical dysplasia on follow-up Pap smears. Secondary 
objectives included determining follow up rate of patients at the clinic as well as the 
correlation between the original Pap smear cytology grade and the histological grade found on 
histology of the LLETZ biopsy. 
 
Methods: A retrospective review of the files of HIV seropositive patients was done at the 
colposcopy clinic at Charlotte Maxeke Johannesburg Academic Hospital after the roll out of 
antiretroviral treatment for the period 1 April 2004 to 31 October 2012. Patients with 
abnormal pap smears during this time were referred to the colposcopy clinic where a 
colposcopy and LLETZ biopsies were done. Demographic and clinical data in regards to age, 
gravidity, contraception, CD4 count, antiretroviral usage, and referral time was collected. Data 
from the clinical description of the colposcopy and histology of the LLETZ biopsy was also 
collected. Patients followed up again after 6 months when a repeat pap smear was done. The 
results of these Pap smears were also collected. Data was then analysed and variate and 
multivariate logistical regression was used to find statistically significant correlations. 
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Results: A total of 480 files were found to have complete clinical records. One hundred and 
sixty eight (42.71%) patients had both endo and ectocervical margins clear. Predictive factors 
for the involvement of endocervical margins was the doctor performing the procedure (p-
value <0.01) cytology of the original Pap smear (p value <0.01) and the grade of histological 
abnormality found at time of LLETZ (p-value <0.01). The statistically significant predictive 
factors for ectocervical margin involvement was the visualization of the transformation zone 
at colposcopy (p-value <0.01), the size of lesion found at colposcopy (p-value <0.01), the use 
of combined oral contraceptive pill (OCP) (p-value 0.02) and the histological grade of 
abnormality found on the LLETZ biopsy. Age, parity, CD4 count, use of antiretroviral drugs, 
length of time from Pap smear to colposcopy and use of contraception other than OCP were 
not found to be statistically significant in our sample population for the involvement of either 
endo or ectocervical margins. 
Statistically significant risk factors for the recurrence of intraepithelial lesions on follow up 
Pap smear was having both endo and ectocervical margin involvement on histology (p-value 
0.01) The Ectocervical margin alone was found to have a p-value of <0.01. Abnormal 
cytology on follow up Pap smear was found in 58.69% of patients. 
The follow up rate at the clinic was 46.04%.  
Correlation of cytological grade and histological grade of cervical intraepithelial neoplasm in 
our sample population was found to be adequate (p-value <0.01).  
 
Conclusion: Incomplete incision of the intraepithelial lesion was found to be a significant risk 
factor for the recurrence of cytological abnormality in patients undergoing LLETZ biopsy. 
Identifying patients at increased risk for recurrence is important to ensure close follow up in 
this patient population. 
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Chapter 1 
 
1.1 Introduction 
 
Cervical cancer remains a major cause of cancer mortality among women in developing 
countries with up to 80% of newly diagnosed cervical cancer cases occurring within these 
regions.(1) Areas with the heaviest burden of disease include Sub-Saharan Africa, Latin 
America, the Caribbean and South East Asia; which have access to less than five percent of 
the world’s cancer resources.(2).Data collection and access to health care in these areas are 
poor and the true incidence is likely to be vastly under reported.(2)  
 
 In South Africa there are an estimated 16.84 million women 15 years and older at risk for 
developing cervical cancer.(3) Cervical cancer is the second most common cancer diagnosed 
in South Africa.(4) Cervical cancer accounts for 23.3% of all cancers in women in Africa.(1) 
Data from the 1998 South African National Cancer Registry (NCR) Report 1998-1999, 
published in 2004(4) reported a lifetime risk of 1 in 26 (0-74years) in all women in South 
Africa and 1 in 21 (0-74years)  in black South African women of developing Cervical Cancer. 
Black South African women are far more likely to develop invasive cancer with 84% of 
cervical cancers reported during this period found in this population group.(4) True cancer 
statistics are difficult to obtain as statistics rely on a passive and voluntary reporting and 
surveillance system (4)and only takes into account histologically confirmed cases. (5) 
 
Unfortunately in poor resource settings the majority of these cancers are diagnosed at an 
advanced stage and mortality approaches 78% compared to the United States where mortality 
is almost half at 40%(6). In America cervical cancer is the 13
th
 most common cancer among 
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women.(7) The incidence according to the WHO of new cases of cervical cancer in the United 
States of America is 7 per 100 000(7) versus South Africa where the incidence is 22.8 per 100 
000(3) highlighting the massive discrepancy of disease burden between developed and 
developing countries..  
 
The discrepancy in cervical cancer statistics between countries can be attributed to the 
implementation of widespread successful cervical screening programmes in developed 
countries.(1) Most developing countries have very few independent screening programmes not 
directly attached to research units.(2)  
 
1.2 Screening for Cervical Cancer 
 
Disease prevention can be divided into primary and secondary prevention.(1) This can be 
applied to cervical cancer. 
 
The World health Organisation (WHO) Wilson-Junger criterion(8) for disease screening is 
almost completely met by cervical cancer screening programs. 
 
Primary prevention focuses on individual behaviour in an attempt to decrease the chance of 
Human Papillomavirus (HPV) infection- a highly infectious, sexually transmitted virus. 
Premalignant lesions of the cervix have been very closely linked to the infection of the cells of 
the transformation zone of the cervix with oncogenic strains of HPV which cause activation of 
oncoprotiens E6 and E7 which in turn inactivate tumour suppressor genes P53 and PRb.(5) 
Strategies include condom use, male circumcision, discouraging smoking, as well as the HPV 
vaccinations.(5) HPV vaccinations ideally need to be administered prior to exposure to HPV. 
The HPV vaccines currently available only provide immunisation against oncogenic HPV 
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subtype 16 and 18 despite there being numerous other oncogenic subtypes known to cause 
cervical cancer.(6) Human immunodeficiency virus (HIV) infected patients are at an increased 
risk of being infected by numerous subtypes of oncogenic HPV such as 33, 35, 52, and 81 but 
16 and 18 remain the most common infective subtype even in this immune suppressed 
group.(1) There is some cross protection between the strains included in the vaccinations and 
those excluded.(5)  
 
By extending coverage to the 8 most common oncogenic strains of HPV, it is postulated that 
up to 95% of cervical cancer could be prevented.(2) Because of the possibility of infection by 
numerous subtypes, cervical screening with cytology must be continued. One fear is that with 
the introduction of vaccination, women may not report for cervical screening.(1) 
 
Secondary Prevention makes use of cervical cytology in the form of the Papanicolaou test 
(Pap test) to detect pre-malignant cervical intraepithelial neoplasia (CIN). These cytological 
findings are reported according to the Bethesda system from 2001.(9) Well established 
screening programmes in Scandinavia have shown that greater population coverage is more 
important than the frequency of screening.(10) Adequate screening could decrease the rate of 
cervical cancer by two thirds.(1,6) The cervical screening programme in South Africa was 
introduced in 2001.(11) These guidelines were developed based on the WHO guidelines for 
screening in middle income developing countries. (12)The South African National guidelines 
state that asymptomatic woman should receive 3 Pap smears in their lifetimes starting at the 
age of thirty, and then one ten years apart. Women over the age of 50 years who had never 
been screened would receive one Pap smear.(6,11) Uptake of these Pap smears has been poor 
with an estimated 20% coverage of the population of Johannesburg through the primary health 
care centres.(10)  
 
Women with abnormal Pap smears showing precancerous lesions must then be referred to a 
centre offering colposcopy where the lesion can be visualised and excised. The most common 
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form of excision done is Large Loop Excision of the Transformation Zone (LLETZ). LLETZ 
is performed on all women with high grade lesions (CIN II and III),where the colposcopic 
finding and cytology finding are discrepant by more than one grade, or who have persistent 
low grade lesions.(10,13) One concern with an increasing level of screening by primary health 
care centres is the inability of referral centres to cope with the number of referrals received 
resulting in long waiting lists and delay of treatment. 
 
Many referral centres have initiated a one step “Look and LLETZ” clinic.(14) In resource 
poor settings where follow-up is notoriously poor, LLETZ at time of first consultation has 
eliminated the risk of patients not returning for definitive treatment after colposcopic biopsies 
were performed. The results from the Look and LLETZ clinics have been satisfactory 
although 15-49% of patients have cytological abnormities on a follow-up Pap smears.(10,14) 
The risk of persistent disease seemed to be greater in HIV positive women, women over the 
age of 50 years, and incomplete excision at either one or both resection margins.(15,16) 
Although treatment of the pre-malignant lesion does decrease the risk of an invasive cervical 
cancer, patients undergoing treatment remain at a 5 times increased risk of developing 
invasive disease and so careful follow up is mandatory with possible retreatment if 
indicated.(16) 
 
The advantage of LLETZ is the retention of fertility with minimal short term 
complications.(13,16) In immune-competent woman LLETZ has been shown to be highly 
effective (90%) in removing the CIN lesion in its entirety. LLETZ has been associated with a 
risk of preterm rupture of membranes and preterm birth.(13)  
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1.3 Cervical intraepithelial lesion and the Human 
Immunodeficiency Virus 
 
The epidemic of Human Immunodeficiency Virus (HIV) infection in Sub-Saharan Africa is 
one of the worst in the world.(1) The HIV epidemic has hit where the incidence of cervical 
dysplasia and cancer is most prevalent.(1)  It is estimated that there are approximately 5.9 
million people in South Africa living with HIV.(17) In 2011 the HIV prevalence in antenatal 
clinics across South Africa was 29.5%.(18) This HIV prevalence has remained fairly stable 
since 2007. The HIV prevalence among the general population has remained at approximately 
17.3% since 2005.(18) 
 
Cervical cancer was added to the list of AIDS defining conditions by the Centres for Disease 
Control (CDC) in 1993. In the same document released by the CDC, emphasis was placed on 
the need for intensive screening to identify and treat cervical dysplasia in an attempt to 
prevent progression to invasive disease(19). 
 
The incidence of HPV infection and intraepithelial lesions in HIV infected women is up to 5 
times higher than the HIV-negative population with between 20-40% of women having CIN 
lesions ranging from LG-SIL to HG-SIL and up to 49% having concurrent infection with 
HPV.(15,20) The number of serotypes of HPV infection, including oncogenic subtypes is far 
more extensive in HIV positive versus HIV negative women. There is also increased 
persistence of the HPV infection with 24 % of HIV positive women having persistent HPV 
infection compared to only 4% in HIV negative woman.(21) Woman co-infected with HIV 
and HPV have shown a decreased regression of low grade lesions and a higher rate of 
progression to a high grade CIN.(21) The size of the CIN lesion is often found to be greater in 
diameter and this in itself may lead to the higher rate of unclear margins found in HIV positive 
women post LLETZ procedure.(22)  
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The progression from pre-malignant lesion to invasive cancer in HIV positive women is 10-15 
years shorter than in HIV negative women. Invasive carcinoma is usually found in patients 
who are profoundly immune-compromised with CD4 counts below 200cells/μl.(1)  
 
It is difficult to tell whether the incidence of cervical cancer has increased due to HIV as there 
is poor record keeping within most developing countries. In developed countries women 
living with HIV have an increased rate of CIN but because of the existence of vigorous 
screening programmes the overall incidence of cervical cancer has remained low.(21) In 
developing countries where the availability of Highly Active Antiretroviral Treatment 
(HAART) has only recently become available it is possible that HIV positive women were 
dying because of opportunistic diseases such as Tuberculosis and Pneumocystis carinii before 
the relatively longer transition from pre-malignant CIN lesions to invasive carcinoma became 
apparent.(21,23)  
 
Studies looking at the introduction of HAART and its effect on HPV and CIN lesions have 
revealed mixed results (21,23) Some studies have shown there may be limited clearance or 
regression of HPV and CIN in HIV positive women on HAART. (21) The regression rates 
between women on HAART and those not on HAART were minimal. The small benefit 
seemed to be in woman who had the greatest response to HAART in terms of CD4 count and 
viral load suppression and those who initiated HAART at higher CD4 counts(21). This may 
imply that cellular genetic changes induced by prior HPV infection, more than the HPV itself, 
may be responsible for the persistence and progression of lesions.(21)  
HIV positive woman should have intensive cervical screening with the HIV Management 
Policy suggesting that annual pap smears should be carried out.(5) (23) Although there is no 
fixed guideline the current opinion is that HIV positive woman should have a Pap smear and 
pelvic exam at time of first presentation and then again twice within the first year of diagnosis. 
If these show abnormal cytology, referral for colposcopy should be done immediately. If they 
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remain normal, Pap smears can then be done on an annual basis.(21) The South African 
cervical screening programme does not take HIV into account. The Western Cape Department 
of Health policy states that annual Pap smears should be undertaken once a diagnosis of HIV 
is made.(15) Unfortunately, research done in the Western Cape by Batra et.al shows poor 
adherence of this guideline, with only 13% of HIV positive patients having had 1 Pap smear. 
(15) 
 
There are a number of areas of concern regarding HIV positive women and our current 
screening and treatment guidelines of HPV and CIN. 
 
Firstly, Shah et al showed poor correlation between the initial cytological diagnosis and that 
found at time of histological diagnosis made at LLETZ in HIV positive patients. Shah’s study 
found only a 42-45% correlation between the Pap smear and histological sample.(24) This 
study had significant limitation in that it was done on relatively small sample size of 71. 
Research done prior to this in 1994 by Wright et al which found the sensitivity and specificity 
of the cervical cytology to be adequate at 81 and 87% respectively when compared to 
histological samples.(25) The question raised by these findings is that of using alternative 
screening modalities in HIV positive patient such as HPV testing or colposcopy.  
 
Another area of concern is the higher rate of involved margins in HIV positive patients as 
shown in a study by Giles in 2005.(20) Positive margins were found in up to 40% of HIV 
positive patients with treatment failure as indicated by a CIN lesion on follow up Pap smears 
was found in as many as 56% of patients in this group.(20) Again this study was done with a 
small sample size of 68. 
 
Foulot et al showed that careful selection of patients according to adequacy of colposcopy and 
size of lesion was important to obtain adequately excised lesions. In his study he 
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recommended the use of electrosurgical conisation over LLETZ for large lesions or an 
inadequate colposcopy. An adequate colposcopy was defined as full visualization of the 
transformation zone.(22) 
 
1.4 Problem Statement 
 
In our population, with a high prevalence of HIV infection, it is of upmost importance to 
ensure that CIN is adequately screened for and treated to prevent the development of invasive 
cervical cancer. It is still uncertain which patients despite positive margins at time of LLETZ 
will go on to develop persistent CIN or invasive disease. 
 
 Patients with certain risk factors which can be identified should possibly have closer 
surveillance. The difficulty is in attempting to identify this high risk group. 
 
The involvement of histological margins after a LLETZ biopsy has been shown to influence 
recurrence of CIN post treatment. (16) Other factors shown to have an influence on CIN 
recurrence are HIV status and CD4 count.(16)  The use of HAART does potentially have a 
protective effect against CIN. The greatest effect is in those patients with the greatest response 
in CD4 count and suppression of viral load.(23)  Unfortunately in our clinic these parameters 
are not routinely collected as there is no integrated system of care between the antiretroviral 
clinics and the colposcopy clinic. This makes adequate surveillance of our patients almost 
impossible. 
 
The higher the grade of CIN excised also is a risk for involved margins and therefore 
recurrence. Dobbs et al attributed this to higher grades having larger lesions as well as 
possible deeper crypt involvement leading to challenge at excision(26).  
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The international federation for Colposcopy and Cervical pathology endorsed a classification 
of the transformation zone. This was based on site, size and visibility.(27) Type 1 has a 
transformation zone that was fully ectocervical had the greatest chance of complete excision. 
In type 2, the full transformation zone is visualised but may have an ectocervical component. 
Type 3 the transformation zone has an endocervical component and is not fully visualized. 
Type 1 had the greatest chance of complete excision with Type 3 having the smallest 
percentage of clear margins.(28) As per Foulot(22) we may need to institute a system of 
careful selection of patients for LLETZ biopsy based on the visualization of the 
transformation zone. 
 
1.5 Study Objectives 
 
Primary Objectives 
The primary study objectives are as follows: 
 
1. To analyse the demographics of the sample population of women presenting for 
treatment at the Charlotte Maxeke Johannesburg Academic Hospital from 1 April 2004 
to 31 October 2012. 
 
2. To determine the risk factors for involved margins of the LLETZ biopsy. 
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Secondary objectives: 
 
1. To determine the follow up rate of patients at the colposcopy clinic 
2. To compare the results of the margins of the LLETZ biopsy to follow up Pap smears 
done after 6 months. 
 
3. To correlate the cytology results of the Pap smear with the histology found at time of 
LLETZ biopsy. 
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Chapter 2 
 
2.1 Methodology 
Study design 
 
This study was a retrospective review of case note files of HIV positive women attending the 
Colposcopy clinic at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in 
Johannesburg, South Africa. This clinic is an Academic unit and is part of the faculty of 
Health Sciences of the University of the Witwatersrand. It is a strictly referral unit accepting 
referrals from local primary health care clinics and general practitioners in the greater 
Johannesburg Metropolitan area. Patients are referred with high grade lesions or persistent low 
grade lesions found on Pap smear. The average waiting time for an appointment at this clinic 
is 3 months. 
 
Population 
 
The sample included all HIV positive patients referred for colposcopy and treatment from the 
roll out of HAART in Gauteng on 1 April 2004 to 31 December 2012. This cohort of patients 
is from a population that does not have access to private health care. HIV diagnosis is done by 
voluntary counselling and testing (VCT) at local primary health centres (PHC) followed by 
CD4 counts when appropriate. HAART is generally initiated at the PHC.  All patients 
attending colposcopy clinic are again offered the opportunity for VCT if their HIV status is 
unknown at time of presentation. As the report of HIV status is verbal and relies on 
forthcoming disclosure, patients who claim to be HIV negative are encouraged to retest.  
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Procedure 
 
Cervical smears done at PHC’s are analysed by the National Health Laboratory Services 
(NHLS) according to the 2001 Bethesda System terminology.(9)  
 
The Clinic offers a “Look and LLETZ” service and is staffed by dedicated nursing sisters and 
doctors. All procedures are performed by fellows in gynaecology oncology or specialist 
gynaecologists.  Colposcopy is done using 3-5% acetic acid followed by the application of 
Lugol`s iodine. Twp percent lignocaine is used to perform a para-cervical block. An 
appropriate sized loop is then chosen to do the LLETZ. 
 
 LLETZ is performed on patients with a high grade CIN lesion (CIN II or higher), if there is 
inadequate colposcopy, or if there is a persistent CIN/ASCUS lesion on repeated Pap smears. 
 
The LLETZ biopsy sample is then placed in formalin solution and is analysed by pathologists 
at the NHLS. Post LLETZ the base of the lesion is cauterised using a roller ball in the hope of 
ablating any remaining cells missed on excision. 
 
Patients then return after 6 months for follow up which includes receiving the result of the 
LLETZ biopsy as well as a repeat pap smear. Involved margins were defined as either 
endocervical margin, ectocervical margin or both margins involved with CIN lesion of any 
grade.  Regardless of the result of the LLETZ biopsy a repeat Pap smear is done at this time 
and the patients are asked to return in 3 months. If this repeat Pap smear shows a high or low 
grade lesion the patient has a repeat colposcopy and LLETZ.  
 
- 24 - 
 
The women’s medical history and results: initial cytology report, HIV result, CD4 count, anti-
retroviral regimen, contraception and histology are kept in a dedicated file in the colposcopy 
clinic thereby minimising the loss of files for review in this study.  
 
Exposure and Outcome Variables 
 
The factors that were reviewed included   
 The experience of the attending doctor doing the LLETZ biopsy 
 Age of patient at presentation 
 Parity and gravidity 
 HIV  and immune status by way of CD4  
 Use and duration of HAART 
 The grade of the original cytological lesion using the Bethseda classification system 
 Time elapsed between the original pathological Pap smear and the LLETZ biopsy 
 Use and method of contraception at the time of the consultation 
 Involved margin of the biopsy: endocervical, ectocervical or both 
 Histology of the LLETZ sample 
 
2.2 Statistics 
 
Data was collected and entered into a Microsoft Excel Software spreadsheet. Descriptive 
statistics were preformed and statements of frequency with percentages and mean with 
standard deviations, or medians with ranges were found. To determine associations between 
the outcome measure and possible determinates, variate and multivariate logistic regression 
were used with statements of odds ratios and 95% confidence interval. Determinants showing 
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p-values of <0.2 on variate analysis were included in the multivariate logistic regression 
model. 
Sample size estimate was based on the possibility that clear margin rate may be decreased 
from 60% to 40% if the CD4 count is lower than 200cells/μl. It was assumed that one third of 
women will have a CD4 count of less than 200calls/μl. To achieve statistical significance for 
this difference at a p-value of 0.05 and with a power of 80%, a minimum of 240 patient files 
had to be reviewed. 
 
2.3 Limitations 
 
Poor record keeping by attending doctor led to a loss of data. Patient files that have missing 
data such as HIV result, CD4 count; poor note keeping around the colposcopic procedure by 
the attending physician were excluded. 
 
2.4 Funding 
 
As this is a retrospective review of files very little funding was required. This study was self 
funded 
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2.5 Ethics and consent 
 
Ethics 
 
Ethics permission has been obtained from the Human Research Ethics Committee (Medical) 
of the University of the Witwatersrand. (See Appendix A) 
 
Hospital Permission 
 
Hospital permission has been obtained from the Chief Executive Officer of Charlotte Maxeke 
Johannesburg Academic Hospital. (See Appendix B) 
 
Consent 
 
As this is an anonymous retrospective review of patient files, patient consent was not required.  
No minors were included in this study. 
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Chapter 3: Results 
 
After the files of the CMJAH Colposcopy clinic were reviewed, 480 files were found to be 
complete with all demographic information as well as clinical data including results of HIV, 
CD4 count and histology results adequately recorded. The time frame for files reviewed was 
from 1 April 2004 to 31 December 2012. 
 
As HIV is self-reported by the patients, the absolute number of patients in our study found to 
be HIV positive may well be under reported. All patients presenting with an unknown HIV 
result or who claim to be HIV negative were strongly encouraged to retest and sent for 
voluntary counselling and testing. In patients with unknown CD4 counts, CD4 counts are 
taken and patients sent for initiation of HAART if appropriate. 
 
3.1 Demographics and Clinical features of Patients 
 
Age and gravidity of study population 
 
The mean age of the study population was 36.10(SD =7.77) with a median age of 35.5(IQR 
=31-40).  The youngest patient in our sample group was 20 and the oldest 64 years of age. 
For statistical analysis in this study the population was divided into 3 groups namely <35, 35-
49, and >49. 
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Table 1: Age in years number(n)=480) 
Age Group Frequency(n) Percentage(%) 
<35 211 43.96 
35-49 237 49.38 
>49 32 6.67 
 
The mean gravidity on our sample population was 2.35(SD=1.30) with a median of (IQR=1-
3). There were 23 women in the study who had never fallen pregnant and 30 who had a 
gravidity greater than 5. The greatest gravidity was 9. 
Again for statistical analysis the patients were divided into 3 groups: gravidity of 0, gravidity 
of 1-2, and gravidity >2 
 
 Table: 2 Gravidity (n=480) 
Gravidity Frequency(n) Percentage(%) 
0 23 4.79 
1-2 269 56.04 
>2 188 39.17 
 
Contraception use 
Contraception in the files was recorded according to what the patient was currently using. No 
mention was made of historic contraceptive use by the patients. Contraception was divided 
into none, combined oral contraception pill (OCP), injectable progesterone (Nur Isterate and 
Depo Provera), intra uterine contraceptive device (IUCD) and condom usage. 
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Table 3: Contraception use (n=480) 
Contraception Frequency(n) Percentage(%) 
None 262 54.58 
Condom 119 24.79 
OCP 23 4.79 
Progesterone 74 15.42 
IUCD 2 0.42 
 
In this category are included patients who desire fertility, are not sexually active or have 
undergone surgical sterilization so may account for the high proportion not using 
contraception. 
 
CD4 Count 
 
CD4 is measured as an absolute value in cells/mmᵌ at time of colposcopy 
 
In our study population the mean CD4 was 316.20 (Standard deviation (SD)190.82). The 
median was 288.5 (IQR=170-423.5) with a range of 7 to 1000 
 
For further analysis the CD4 count was divided into 3 groups namely <201, 201 to 350, and 
>350. 
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Table 4:CD4 count (n=480)  
CD4 count Frequency(n) Percentage(%) 
≤ 200 155 32.29 
201-350 141 29.38 
>350 184 38.33 
 
Antiretroviral use 
 
Table 5: Antiretroviral use (n=480) 
On ARVs Frequency(n) Percentage(%) 
Yes 232 48.33 
No 248 51.67 
 
The duration of HAART use nor patients response to the use of HAART in terms of absolute 
CD4 count or viral load are not recorded in the files at the colposcopy clinic. 
 
Referral time 
 
This was defined as the time taken from the day of first presentation for a Pap smear at the 
primary care centre to the day the first colposcopy was done at CMJAH Colposcopy clinic. 
The mean was 186.49 days (SD 150.55). The median was 152 (IQR 110-210.5).  The range 
was 27-1769 days. 
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For analytical purposes this group was divided into 3 groups namely less than 180 days, 180 
to 365 days, and greater than 365 days. 
 
Table 6: Referral time from original Pap smear to colposcopy (n=480) 
Time in days Frequency(n)  Percentage(%) 
<180 319 66.46 
180-365 123 15.63 
 >365 38 7.92 
 
3.2 Colposcopy and histology LLETZ biopsy samples 
 
Cytology of referral Pap smear 
 
Table 7: Cytological grade of CIN lesion on referral Pap smear (n=480) 
Cytological grade Frequency(n) Percentage(%) 
ASCUS 19 3.96 
HGSIL 401 83.54 
LGSIL 60 12.50 
 
The vast majority of patients referred had HGSIL on their referral Pap smear which was to be 
expected considering the referral criteria for the colposcopy clinic. 
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Size of CIN lesion at colposcopy 
 
The size of the lesion was judged completely objectively by the surgeon doing the colposcopy 
and was marked on a diagram within the patients file. There was no way to verify the size of 
the lesion or by which standard the surgeon sized the lesion. 
 
Table 8: Clinical impression of size of CIN lesion (n=480) 
CIN Size Frequency(n)  Percentage (%) 
Small 172 35.83 
Medium 171 35.63 
Large 137 28.54 
 
Transformation zone visualized at time of colposcopy 
 
The transformation zone was noted to be visualized in 340 (70.83%) of patients undergoing 
colposcopy. In 140 (29.17%) of the patients the transformation zone was not seen. 
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Histology of LLETZ biopsy 
 
Table 9: Histology of LLETZ biopsies (n=480) 
Histology Result Frequency(n) Percentage(%) 
CIN1 86 17.92 
CIN2 152 31.67 
CIN3/Ca in-situ 242 50.42 
 
Of these colposcopic LLETZ biopsies done, 168 (35.21%) had clear margins. 275 (57.29%) 
had involved margins.    
In 36 (7.50%) specimens the pathologist was unable to comment on the involvement of the 
margins. Reasons given for the inability to comment on involvement of margins in the 
pathology reports included severely traumatised specimens, significant cautery artifact, failure 
to orientate the specimens, or the specimens being submitted in multiple small fragments. 
 
Histological involvement of the excised margins 
 
Table 10:  Involvement of margins (n=480) 
Margin involved Frequency(n) Percentage(%) 
Unsure 36 7.50 
Both margins clear 169 42.71 
Endocervical 117 24.38 
Ectocervical 57 11.88 
Both margins involved 101 21.04 
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Patients with unsure margins were excluded from further analysis. Because of this our study 
population was reduced to 444 participants. The number of specimens with any positive 
margins was combined and found to be 275(61.94%) The endocervical margin was clear in 
226(50.90%) of specimens. Ectocervical margin was found to be clear in 286 (64.41%) of 
specimens. 
 
Treating Doctor 
 
Table 11: Clear and involved margins obtained by each treating doctor 
(n=444) 
Doctor 
code 
Involved Margins Clear Margins Total of 
patients 
treated by 
Dr 
Frequency(n) Percentage(%) Frequency(n) Percentage(%) 
1 74 69.81 32 30.19 106 
2 40 43.48 52 56.52 92 
3 23 71.88 9 28.132 32 
4 108 68.35 50 31.65 158 
5 8 72.73 3 27.27 11 
6 9 56.25 7 43.75 16 
7 2 22.22 7 77.78 9 
8 11 55.00 9 45.00 20 
 
Doctor 2 was used for further statistical analysis as they had the greatest clear margin rate and 
treated a significant number of patients. 
- 35 - 
 
 
3.3 Patient follow-up at CMJAH colposcopy clinic 
 
Two hundred and twenty one (46.04%) patients did not come back to the colposcopy clinic for 
follow-up Pap smears. We cannot exclude that these patients did not follow up at other 
institutions or returned to their primary health centres for their follow-up Pap smears.  
 
The table below demonstrates the follow-up Pap smear results of patients who did return to 
the colposcopy clinic. 
 
Table 12: Follow up Pap smears (n=259) 
Cytology Grade Frequency(n) Percentage(%) 
Normal 107 41.31 
ASCUS 12 4.63 
HGSIL 60 23.17 
LGSIL 80 30.89 
 
3.4 Prediction of positive margins 
 
This was divided into endocervical and ectocervical margin involvement to determine 
independent risk factors for each. An analysis of the data was done according to each of the 
risk factors for which we had available data. A p-value was then calculated with significance 
being set at <0.05. 
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Endocervical Margins 
 
Table 13: Predictive factors for involved endocervical margins  
Predictor Involved 
margins 
n=218,(%) 
Clear Margins 
n=226,(%) 
P value 
Age <35 
35-49 
>49 
97(49.49) 
107(48.64) 
14(50) 
99(50.51) 
113(51.36) 
14(50) 
0.98 
CD4 count >350 
201-350 
<201 
84(49.12) 
56(43.75) 
78(53.79) 
87(50.88) 
72(56.25) 
67(46.21) 
0.25 
Gravididty 0 
1-2 
>2 
8(36.36) 
124(49.80) 
86(49.71) 
14(63.64) 
125(50.20) 
87(50.29) 
0.47 
HAART No 
Yes 
109(50.93) 
109(47.39) 
105(49.07) 
121(52.61) 
0.46 
Doctor 2 No 
Yes 
196(55.68) 
22(23.91) 
156(44.32) 
70(76.09) 
<0.01 
Cytology 
group 
LGSIL/ASCUS 
HGSIL 
24(32.00) 
194(52.57) 
51(68.00) 
175(47.43) 
<0.01 
CIN Size Small 
Medium 
Large 
71(44.94) 
76(48.10) 
71(55.47) 
87(55.06) 
82(51.90) 
57(44.53) 
0.20 
TZ Seen no 
yes 
55(43.65) 
163(51.26) 
71(56.35) 
155(48.74) 
0.15 
Time to 
referral 
<180 
180-365 
141(48.62) 
58(49.57) 
149(51.38) 
59(50.43) 
0.95 
- 37 - 
 
>365 19(51.35) 18(48.65) 
Contraception None 
Condom 
OCP 
Progesterone 
IUCD 
107(44.96) 
66(58.41) 
12(52.17) 
32(47.06) 
1(50.00) 
131(55.04) 
47(41.59) 
11(47.83) 
36(52.94) 
1(50.00) 
0.22 
Hormonal 
contraception 
No 
Yes 
174(49.29) 
44(48.35) 
179(50.71) 
47(51.65) 
0.87 
OCP No 
Yes 
206(48.93) 
12(52.12) 
215(51.07) 
11(47.83) 
0.76 
Depot 
Progesterone 
No 
Yes 
186(49.47) 
32(47.06) 
190(50.53) 
36(52.94) 
0.72 
LLETZ 
Histology 
CIN 1 
CIN 2 
CIN 3 
7(9.09) 
68(49.64) 
143(62.17) 
70(90.91) 
69(50.36) 
87(37.83) 
<0.01 
; 
Table 14 Logistic regression model for prediction of clear endocervical 
margins 
 Adjusted Odds 
Ratio 
95% Confidence 
Interval 
P value 
LLETZ histology CIN1 
(reference) 
LLETZ histology CIN2 
LLETZ histology CIN3 
1.00 
 
0.10 
0.07 
- 
 
0.41-0.23 
0.28-0.15 
- 
 
<0.01 
<0.01 
Other Doctors (reference) 
Doctor 2 
1.00 
3.84 
- 
2.21-6.66 
- 
<0.01 
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Ectocervical Predictors for Involved margins 
 
Table 15: Predictors of positive ectocervical margins  
Predictor Involved 
margins 
n=218  
n(%) 
Clear Margins 
n=226 
n(%) 
P value 
Age <35 
35-49 
>50 
77(39.29) 
71(32.27) 
10(35.71) 
119(60.71) 
149(67.73) 
18(64.29) 
0.33 
CD4 count >350 
201-350 
<201 
56(32.75) 
42(32.81) 
60(41.38) 
115(67.25) 
86(67.19) 
85(58>62) 
0.21 
Gravidity 0 
1-2 
>2 
8(36.36) 
85(34.14) 
65(37.57) 
14(63.64) 
164(65.86) 
108(62.43) 
0.77 
HAART No 
Yes 
73(34.11) 
85(36.96) 
141(65.89) 
145(63.04) 
0.53 
Doctor 2 No 
Yes 
133(37.78) 
25(27.17) 
219(62.22) 
67(72.83) 
0.06 
Cytology 
group 
LGSIL/ASCUS 
HGSIL 
24(32.00) 
134(36.31) 
51(68.00) 
235(63.69) 
0.47 
CIN Size Small 
Medium 
Large 
37(23.42) 
51(32.28) 
70(54.69) 
121(76.58) 
107(67.72) 
58(45.31) 
<0.01 
TZ Seen No 
Yes 
30(23.81) 
128(40.25) 
96(76.19) 
190(59.75) 
<0.01 
Time to <180 101(34.83) 189(65.17) 0.51 
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referral 180-365 
>365 
46(39.32) 
11(29.73) 
71(60.68) 
26(70.27) 
Contraception None 
Condom 
OCP 
Progesterone 
IUCD 
80(33.61) 
45(39.82) 
3(13.04) 
29(42.65) 
1(50.00) 
158(66.39) 
68(60.18) 
20(86.96) 
39(57.35) 
1(50.00) 
0.09 
Hormonal 
contraception 
No 
Yes 
126(35.69) 
32(35.16) 
227(64.31) 
59(64.84) 
0.93 
OCP No 
Yes 
155(36.82) 
3(13.04) 
266(63.18) 
20(86.96) 
0.02 
Depot 
Progesterone 
No 
Yes 
129(34.31) 
29(42.65) 
247(65.69) 
39(57.35) 
0.19 
LLETZ 
Histology 
CIN 1 
CIN 2 
CIN 3 
8(10.39) 
40(29.20) 
110(47.83) 
69(89.61) 
97(70.80) 
120(52.17) 
<0.01 
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Table 16: Logistic regression model for the prediction of clear ectocervical 
margins 
 Adjusted 
odds ratio 
95% Confidence 
interval 
P value 
Non OCP Use(reference) 
OCP use  
- 
3.35 
- 
0.99-12.64 
 
0.052 
LLETZ histology 
CIN1(reference) 
LLETZ histology CIN2 
LLETZ histology CIN3 
- 
0.26 
0.13 
- 
0.11-0.61 
0.06-0.29 
 
<0.01 
<0.01 
CIN lesion small or medium 
(reference) 
CIN large 
- 
 
0.36 
- 
 
0.23-0.57 
 
 
<0.01 
 
3.5 Results of Secondary Objectives 
 
Follow-up rate at CMJAH colposcopy clinic 
 
Of the 480 patients seen at the clinic 221(46.04%) did not return for a follow-up Pap smear.  
Two hundred and fifty nine (53.95%) followed up and the results of their repeated Pap smear 
were analysed for the risk factors for recurrence of the intra epithelial lesion. 
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Risk factors for recurrence of intraepithelial lesion on follow up 
Pap smear 
 
Table 17: Risk factors for recurrence of CIN lesion at time of follow-up Pap 
smear. 
 Cytology of follow-up Pap smear P 
Value Normal ASCUS LGSIL HGSIL 
Both Margins 
clear 
No 
Yes 
54(35.29) 
40(47.62) 
4(2.61) 
6(7.14) 
49(32.03) 
27(32.14) 
46(30.07) 
11(13.10) 
0.01 
Endocervical 
margin clear 
No 
yes 
47(38.21) 
47(41.23) 
4(3.25) 
6(5.26) 
37(30.08) 
39(34.21) 
35(28.46) 
22(19.30) 
0.38 
Ectocervical 
margin clear 
No 
yes 
25(28.41) 
69(46.31) 
1(1.14) 
9(6.04) 
32(36.36) 
44(29.53) 
30(34.09) 
27(18.12) 
<0.01 
Histology of 
LLETZ 
biopsy 
CIN1 
CIN2 
CIN3 
20(45.45) 
29(36.71) 
58(42.65) 
 
3(6.82) 
4(5.06) 
5(3.68) 
18(40.91) 
23(29.11) 
39(28.68) 
3(6.82) 
23(29.11) 
34(25.00) 
0.142 
 
Both margins clear on histology were found to be significant with a p-value of 0.01. A clear 
ectocervical margin was found independently to be significant in regards to follow-up Pap 
smear results. 
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Correlation of cytology and histology 
 
Table 18: Correlation of cytology of original Pap smear cytology and histology 
found at time of LLETTZ.  
 Histology of LLETZ  P value 
CIN 1 CIN 2 CIN3 
Cytology of 
original pap 
smear 
ASCUS 
LGSIL 
HGSIL 
9(47.37) 
30(50.00) 
47(11.72) 
4(21.05) 
17(28.33) 
131(32.67) 
6(31.53) 
13(21.67) 
223(55.61) 
<0.01 
 
The correlation of original cytology with the histology was found to be adequate. 
 
  
- 43 - 
 
Chapter 4: Discussion of Results 
 
4.1 Study group demographics 
 
Age and gravidity 
 
The mean age of our study population was relatively low at 36. This is especially true when 
one takes into account that the South African cervical screening programme states that 
cervical screening should only begin at age 30(11). There were 116(24.16%) patients seen at 
the colposcopy clinic who were 30 years and younger. Although this shows that national 
guidelines may not be being followed it does perhaps suggest that patients who are diagnosed 
as HIV positive are having Pap smears done at their primary health care centres despite their 
age. This does follow suggestions by the Western  Cape Department of Health as well as 
Palefsky et al(21) who recommend a pap smear be done at time of first diagnosis of HIV and 
then annually thereafter.(15) 
 
The younger age of this referred population is also important because invasive cervical cancer 
seems to present 10-15 years earlier in the HIV infected population(29) indicating the need for 
earlier and more intensive screening. It may also indicate that there are a significant number of 
women with cervical dysplasia under the age of 30 and that including this group into a 
national screening programme may be beneficial. 
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The gravidity of the study group was also relatively low with a mean of 2.35. This again may 
be attributed to the relatively young nature of our population group still within their 
reproductive years. 
 
Contraception 
 
Barrier method contraception in the form of condoms was low at 24.79%. In a population 
group infected with sexually transmitted infections such as HIV and HPV, one would hope 
that condom use would have been significantly higher. MacPhail et al found that despite good 
education and knowledge of HIV and its route of transmission, there are still many factors 
preventing condom use. These included lack of perceived risk of infection, peer norms, lack of 
condom availability, economic context of sexual relationships and gendered power relations. 
In his study 69% of respondents never used condoms with 16.7% reporting occasional use and 
only 14.3% reporting regular condom usage.(30) Lack of condom use has also shown a 
greater chance of persistence of HPV oncogenic strains and so may lead to higher rates of 
intraepithelial neoplasia and invasive cancers.(31)This is clearly an area of concern and 
indicates a clear need for further intensive education programmes.  
OCP which has a known association with cervical cancer (32) was used by only 4.79% of our 
study population. 
 
CD4 and HAART use 
 
Almost half our study population was using HAART (48.33%). We did not have access to 
information as to the duration of treatment; regimens or response to HAART as it was not 
recorded within the patient files. This is unfortunate as it is the response to HAART in terms 
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of viral load suppression and improvement in CD4 count which is thought to be significant in 
the clearance of intraepithelial lesions and HPV infections.(21) 
 
The mean CD4 count was 316.20(SD 190.82). The lower the CD4 count the greater the 
incidence of HPV persistence on CIN lesions. Moodley et al(33) found a 41-fold increased 
risk of any grade of CIN lesion if women were infected with HPV and HIV. Firnhaber et al 
found that if CD4 was < 200cells/cmᵌ the prevalence ratio of HGSIL and LGSIL was 2.5 
versus if the CD4 count was >500cells/cmᵌ and did not find any significant affect of HAART 
on the outcomes.(34) This emphasises the need for intensive cervical screening of our HIV 
positive patients who have had a CD4 count fall below 200cell/cmᵌ and the need to initiate 
HAART at a higher CD4 count. 
  
Referral time 
 
 It is encouraging to see that the majority of our patients (66.46%) were seen at the colposcopy 
clinic in under180 days.  A study by Saayman et al (35) did not show any significance in a 
greater time delay in the progression of CIN lesions at more than 180 days. Our range was 
very large with the longest time delay of 1769 days. Once again educating patients in the 
purpose and results of the Pap smear may help to significantly decrease the time it takes the 
patients to collect results from the primary health care centres and to make an appointment to 
get seen at the colposcopy clinic itself. 
 
Fully booked clinics may also contribute to time delay from Pap smear to colposcopy and so 
assessment the available resources in terms of adequately trained staff as well as equipment 
needs to carried out. 
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Description of referral cytology and colposcopic lesions seen  
 
The majority of patients (83.54%) who presented to the CMJAH colposcopy clinic had high 
grade lesions on their original Pap smears done at their primary health care providers. This is 
in keeping with the clinic protocol that will see patients either with a high grade intraepithelial 
lesion or with repeated low grade lesions. 
 
On colposcopy the clinical impression of the lesion size was documented as well as the 
visualization of the transformation zone. This is deemed important as Foulot et.al (22) has 
shown that careful patient selection for a LLETZ biopsy is important for good outcomes and 
an adequately excised lesion. In our study population, the transformation zone was not 
visualized in 29.17% of cases. The lesion was deemed “large” in 28% of patients. One must 
question whether these patients may have been more appropriately treated with a cone biopsy. 
It must also be taken into account the impression of size of the lesion is purely objective and 
there is no way to verify the actual size of the lesion seen. 
 
Treating Doctor 
 
Doctor 2 had significantly lower involved margin rates compared to all other doctors working 
at the colposcopy clinic (56.52%). Doctor 7 had excellent clear margin rates but saw a small 
number of patients and so the significance of his/her success rate cannot be varified. What 
became apparent was that years of experience did not seem to impact on the clear margin rate 
but perhaps it is more the individual doctors’ technique which plays a greater role. 
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4.2 Risk Factors for Involvement of Margins on Histology 
 
In the analysis of our data we found that 169(42.71%) had clear margins. The clear excised 
margins is similar to those reported by Adam(16) at Chris Hani Baragwaneth Hospital 
colposcopy clinic: a sister unit within the University of the Witwatersrand, where the clear 
margins were 42.96%. The incomplete excision rates vary widely in published data from 5-
51%.(28) Margin involvement is far more common in HIV infected women versus their HIV 
negative counterparts. (20,24) Higher margin rate involvement is likely due to the larger size 
of lesions and perhaps crypt involvement in HIV positive women.(24) 
The results were divided in to clear margins for endocervix versus ectocervix as it was found 
that there were different risk factors that were significant for each group. 
 
Risk factors for endocervical margin involvement 
 
When the data was analysed, age, gravidity, CD4 count, use of HAART was not found to be 
significant. A higher CD4 count has in other studies been shown to decrease the positive 
margin rate and it is suspected that the stronger the immune system the more likely it would 
be that local immunity at the cervical level would be able to keep the size and depth of the 
CIN lesion small.(24)  A lower CD4 count may contribute to the development of the lesion 
but once the lesion is established the progression of the disease process is not affected by the 
CD4 count.(36) Patients older than 50 years of age are also thought to be at risk for recurrence 
and involved margins. In our study the age of the patients was not significant but our group of 
patients older than 50 was small with only 28 patients and so may have been underpowered to 
obtain a significant result. 
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 Surprisingly the visualization of the transformation zone and size of lesion did not appear to 
play a significant role either. This is against data that suggests that larger type 3 
transformation zone with extension into the endocervix has twice the risk of incomplete 
excision at the endocervical margin.(28) 
 
The cytological grade of the original pathological Pap smear was a found to be statistically 
significant with a p-value of <0.01. The higher the grade of intraepithelial lesion on the 
original Pap smear resulted in a greater chance of having involved margins. High grade 
intraepithelial lesions are a well-known risk factor for positive margins as well as recurrence. 
(37) 
 
The rate of clear margins obtained by Doctor 2 was statistically (p-value <0.01). Doctor 2 was 
not the most experienced doctor in the study which suggests that his/her technique was the 
significant factor. There is a possibility that this doctor removed a greater volume of cervical 
tissue at time of the LLETZ or that he/she extended his biopsy higher up in to the endocervix. 
Unfortunately neither the depth of tissue nor volume of biopsy sample is reported as a 
standard on our pathology reports. The danger with overzealous excision is that there may be 
long term consequences for the patients in terms of preterm labour with an increase risk of 1.7 
(95%CI 1.2-1.4).(28) The pregnancy associated risks have been shown to increase once the 
depth of excision exceeds 10mm with a 3 fold increase if the volume exceeds 6cmᵌ.(28) There 
is also an increased risk of small gestational babies and preterm rupture of membranes. 
Despite this there is a smaller chance of adverse outcomes, short and long term, after LLETZ 
as compared to a cone biopsy. The risk of cervical stenosis post LLETZ is less than 1% and 
quoted as 1.3% if he excision depth is deeper than 14mm.(37) Despite the risks associated 
with LLETZ biopsy it is still the preferred method of treating high grade lesions in young 
women of child bearing age.(28) 
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Contraception of any type (hormonal or non-hormonal) did not provide significance at the 
endocervical margin. 
 
A prolonged pap to colposcopy time did not influence the clear margin rate (p-value =0.95). 
 
A direct significant relation was found when comparing the histological grade of CIN from 
the LLETZ biopsy to the clear endocervical margin. Approximately 90% of patients with 
CIN1 on histology had clear endocervical margins versus 37.83% with CIN3. This is 
concerning as the progression of CIN 3 to invasive cancer is 31-51% over 30 years.(38) 
McCredie’s study was not on HIV positive patients and as discussed earlier the progression 
from CIN to invasive cancer appears to occur 10-15 years earlier in immune-compromised 
patients.(29) Compounded by our poor follow up rate, these patients are at significant risk for 
the development of invasive cancer in their future. 
 
After the logistical regression and adjustment of confounding factors, (See table 15) the 
adjusted odds ratio was 0.07 for having clear endocervical margins if the histology was CIN3. 
The adjusted odds ratio for Doctor 2 was 3.84 and so remained significant for clear margins at 
the endocervical border. 
  
Risk factors for the involvement of margins at the ectocervix 
 
The predictive risk factors for endocervix were similar to those for the ectocervix. 
 
Once again age, CD4 count, use of HAART, gravidity, and time to referral were not 
significant. 
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The grade of cytology of the original Pap smear was found not to be significant in the group 
with involved ectocervical margins with a p-value of 0.47. The cytology of the Pap smear was 
significant for involved endocervical margins. 
 
The findings associated with Doctor 2 approached significance with a p-value of 0.06 which 
may imply that his LLETZ biopsies may have been deeper than they were wide. 
 
CIN lesion size as perceived by the operating doctor was found to be significant with a p value 
of <0.01. The larger the lesion the more difficult it would be to excise completely without 
being overly radical in the process. This may imply that perhaps in patients where the lesion is 
very large a different mode of treatment such as a cone biopsy should be employed. 
 
Strangely enough the visualization of the transformation zone was significant for clear 
ectocervical margins but not for endocervical margins. One way of explaining this may be that 
because the transformation zone was visualized, that perhaps the full extent of the lesion could 
be seen and targeted at the time of the LLETZ biopsy and so achieved complete excision. 
 
Contraception as a whole (barrier and all hormonal methods included) was not significant. But 
when the combined oral contraceptive pill was analysed as a standalone variable it was found 
to be significant with a p-value of 0.02.  This implied that the group using OCP had a higher 
rate of clear margins. This was an interesting finding as the long term use of OCP has been 
shown to be a risk factor for the development of invasive cervical cancer in patients who are 
exposed to HPV.(39) The exact mechanism of hormonal influence is unclear. Exogenous 
hormonal influence may promote the integration of HPV DNA into the host genome which in 
turn causes deregulation of E6 and E7 which are related to the oncogenic potential of HPV 16 
as discussed earlier. Exogenous estrogen may also cause reactivation of HPV or persistence of 
the infection.(40)  Despite this marginally increased risk it is still thought that the benefits of 
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contraception with OCP outweigh the risk it poses. There should be an effort to actively 
include long term users of OCP in screening programmes. (39)  
One way of explaining our results in regards to OCP use may be that the squamocolumnar 
junction migrates under the influence of oestrogen, both endogenous and exogenous, causing 
ectropion. Because of this the transformation zone may have been better visualized and so a 
greater chance of achieving clear margins at time of LLETZ biopsy. 
 
The histology of the LLETZ biopsy was found to be significant for ectocervical margin 
involvement (p-value <0.01). This would be for similar reasons as discussed above. 
 
On the multivariate regression model that was done (see table 17), oral contraceptive use 
remained a significant predictive factor with an adjusted odds ratio of 3.35 and a confidence 
interval of 0.99-12.64,.As for the endocervical margins, the LLETZ histology also remained 
significant despite the size of the lesion or OCP use in the regression model with CIN 3 
having the adjusted odds ratio of 0.13 with a 95% confidence interval of 0.06-0.29 and a p 
value of <0.01.  A large intraepithelial lesion seen at time of colposcopy also remained 
statistically significant in the logistical regression. 
 
4.3 Patient Follow-up 
 
Follow-up of Patients at CMJAH Colposcopy clinic 
 
The protocol for follow-up at our clinic is for the patients to return 6 months after the LLETZ 
for the results of their biopsy as well as a repeat Pap smear. Our follow up rate was 
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disappointingly low with only 259 (53.95%) of patients returning after 6 months. Both local 
and international studies have shown similarly low rates of follow-up in HIV infected 
populations.(10,41) This can be explained perhaps by a generally lower education level, and 
poorer socioeconomic background in this group of patients.(41)  
 
In patients who have clear margins at time of LLETZ, cytological follow-up is adequate. In 
those with positive margins follow up with colposcopic and cytological methods is 
recommended.(26) A meta-analysis of 35 109 women in 66 different studies done by Ghaern-
Maghami et al advised that patients who had deep or endocervical margins involved at time of 
LLETZ should have a repeat procedure as they are at significant risk for recurrence of high 
grade lesions and, in the long term, invasive cancer.(42)  
 
By identifying pre-procedure risk factors or risk factors at time of LLETZ for positive 
margins, patients can be counselled accordingly for their risk of positive margins and 
recurrence at the time of their colposcopy appointment. Hopefully with better education and 
counselling at this first point of contact, follow-up rates can be improved. 
 
Risk Factors for recurrence of cervical intraepithelial lesions on 
follow-up Pap smear 
 
Our study found that if both margins of the LLETZ biopsy were found to be clear on 
histology, the recurrence rate at follow up cytology was significantly decreased with a p-value 
of 0.01. When analysing the margins divided into endo or ectocervical margins only, the 
ectocervical histology was found to be significant. This does go against other studies where 
the involvement of the endocervical margin appeared to be more significant in the persistence 
or recurrence of CIN.(16,41) There is a possibility that the group in this study was too small to 
yield statistical significance. 
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The grade of lesion found at histology was found not to be statistically significant (p-value 
0.14). 
 
HIV in itself is an independent risk factor for recurrence or reactivation of CIN. The 
management of CIN in these patients is extremely difficult and more intensive follow up of 
these patients is required from the time of diagnosis. Some studies have suggested that there is 
a decrease in recurrence in patients on HAART.(20) It is therefore important to encourage the 
initiation and adherence to HAART in this high risk group of patients. 
 
Correlation of results of Pap smear cytology to histology of the 
LLETTZ Biopsy 
 
There are findings that the cytological screening in HIV positive patients is not reliable with 
differing grades of intraepithelial lesion found when doing colposcopiclly directed 
biopsies.(24) This may be due to severe cervicovaginal infections which are common within 
this group. Wright et al (25) found that correlation between the cytology and the histology 
does appear to be adequate. The results of the analysis of our data echoed findings of local 
studies by Adam et al(10) who found an 80.2% correlation between the cytology and 
histology.  
In my study the correlation was found to be appropriate with a p-value of <0.01. 
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4.4 Strengths of this study 
 
The strength of this study lays in the large number of HIV positive patients records that 
underwent analysis. With the HIV endemic in South Africa, the more information we can 
gather on the effects of HIV and HAART on disease progression the more likely we will be to 
offer our patients appropriate management 
 
4.5 Limitations 
 
 This was a retrospective study. There were a significant number of patient records which 
could not be included in the study because of missing data, poor record keeping and 
inadequate clinical notes made by the attending doctors.  
 Antiretroviral use: there was no information recorded in most of the files on the duration 
of use of HAART or the regimen the patient may have been on. Also the response to 
HAART was not documented either in improvement of CD4 count or the suppression of 
the viral load. Most patients receive their HIV treatment at dedicated HIV clinics either 
within CMJAH or at their local primary health care centres spread across the greater 
Johannesburg metropolitan area. This information may well be held at these locations 
and attaining this information and reassessing the clear margins and recurrence in light 
of these factors could be an area for future research in our unit. 
 Other risk factors for CIN: HPV testing is not available within our setting of public 
practice. Smoking was not recorded in the patients’ files. A detailed sexual history with 
regards to safe sexual practices or number of sexual partners was not recorded. 
 HIV: the HIV result is self-reported by the patient. In South Africa there is still 
significant stigma around the disease and patients may not be willing to disclose a 
positive result even to a health worker. Those who claim to be negative are sent for VCT 
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at time of colposcopy. If the result was then found to be positive, these patients were 
then included into the study. There is a possibility of significant under reporting of HIV 
status by patients and so there may have been patients who would have inadvertently 
been left out of our study. 
 Contraception: was recorded as current contraception. No information was available 
with regards to the historic use of different methods. 
 Clinical description of the lesion and TZ: this is an objective impression by the different 
doctors and was recorded on a diagram in the patients’ files or described by the doctor 
within the file as a small, medium or large lesion. There was no method to standardise 
their findings or to determine the actual measurements used as “small”, “medium” or 
“large”. 
 The indication for doing the original Pap smear was not known.  
 We do not have the depth or volume of LLETZ specimen excised. This may have given 
us some idea as to why certain doctors seemed to have improved clearance margin rates 
versus others.  
 The poor follow-up rate after 6 months cause a possible under powering of statistics 
surrounding recurrence rates and correlation of cytology to histology. 
 The correlation of initial cytology to histology appears to be good. But the gold standard 
would be to compare histology of colposcopically directed biopsy specimens done 
before the LLETZ to the histology of the LLETZ sample. 
 Follow-up at 6 months is a relatively short follow up period. Ideally all patients who are 
HIV positive should be followed up for a number of years to ensure the clearance CIN. 
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Chapter 5:  
Conclusion 
 
South Africa is in the midst of an HIV epidemic. The HIV prevalence in antenatal clinics in 
2011 was 29.5%.(18) This is a cross section of the sexually active proportion of our 
population and is also the proportion of women at risk for the development of CIN and 
eventually invasive cervical cancer. The burden on gynaecological and oncology services is 
overwhelming. Countries with well-established screening and treating facilities have managed 
to massively reduce the burden of invasive cancer.(2) 
 
Intensive follow up of high risk patients is vital. It is already well accepted that HIV in itself is 
a risk factor for the development of CIN as well as invasive cervical cancer. In our study we 
attempted to define further which of these patients may fall into a group of even higher risk 
for recurrence of CIN. Of significance were involved margins (either endo or ectocervical) 
with involved ectocervical margins providing the greatest predictive factor.  
 
The involved margin rate was relatively high when compared to international figures in 
patients who were HIV negative but appeared to be on par with studies done with a similar 
patient demographic. 
 
A lower CD4 count or the use of HAART did not have a significant impact on the 
involvement of margins at histology. But due to the retrospective nature of our study, there 
was a significant amount of data around the use of HAART and response to HAART which 
was not available to us. 
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The use of the combined oral contraceptive pill improved clear margin rates at the 
ectocervical margin quite significantly. A well visualized transformation zone, and a small or 
medium size lesion was also found to improve clear margin rates at time of LLETZ biopsy. 
 
The operating doctor made a statistical significant difference. This was not related to years of 
experience and was thought to be due to operative technique. A review of operative technique 
within the department may be warranted when faced with such a vast range in the clear 
margin rates. A follow-up of these patients in years to come may also prove to be interesting 
to determine if the patients seen by the various doctors may have higher complication rates in 
future pregnancies. 
 
Our poor follow up rates may be an indication of the poor counselling and knowledge of our 
patients regarding the purpose of procedures undertaken and the need for intensive follow up. 
This may be an indication that even within an exceptionally busy colposcopy unit, a few extra 
minutes should be taken to ensure the patient understands the condition and the need for 
follow up or repeat procedures over a number of years. 
 
  
- 58 - 
 
 Chapter 6: 
Recommendations 
 
Our study has confirmed risk factors found in other studies done on population groups with 
similar demographics both internationally and locally for involved margins and recurrence.  
 
We could improve our service by doing HPV serotyping. In this way we could identify those 
patients who are at higher risk for invasive disease. These patients could then be kept in a high 
risk clinic and perhaps offered more intensive follow up. The HPV vaccines, although 
available in South Africa, are not yet a part of our Extended Programme of Immunization 
(EPI) as offered by the department of Health due to cost. Including the HPV vaccine may be a 
way to significantly reduce the burden of CIN as well as invasive cancer in future generations. 
The South African Department of Health is hoping to start the roll out of the vaccine in some 
of the poorest communities starting in Feburary 2014 and has encouraged parents who can 
afford the cost of the vaccine to purchase the vaccine for their daughters. The impact of this 
vaccine will be fascinating to witness in the years to come. 
 
A review of the current National Guidelines for Cervical Cancer Screening should be 
undertaken taking into account the HIV status of the patients. Most HIV positive patients are 
offered one Pap smear at time of diagnosis but this should be formalized into a national 
guideline to ensure greater coverage and adherence. The frequency with which these patients 
should receive Pap smears and how to manage abnormal results should also be formalized 
with clear routes of referral to colposcopy clinics manned with well-trained colposcopists. 
 
A prospective study in which all variables could be adequately and completely collected may 
provide a better understanding of how HIV, HPV subtypes, CD4, HAART and different 
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regimes, and response by way of viral load has on the clear margins as well as recurrence rates 
of CIN. 
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Appendix C: Data Capture Sheet 
 
Record Number: 
Date of LLETZ Preceedure: 
Age  
Parity  
Gravidity  
Doctor code A B C D E F G H 
Contraception Yes No 
Type of 
Contraception 
None OCP Depo provera IUCD Condoms 
CD4  
HAART Yes No 
Duration of 
HAART 
 
Date of original 
Pap smear 
 
Days elapsed 
between original 
pap and LLETZ 
procedure 
 
Grade of original 
CIN Lesion 
ASCUS LGSIL HGSIL 
Clinical size of CIN 
lesion 
Small Medium Large 
Involvement of 
Transformation 
Zone 
Yes No 
Clear resection 
margins 
Yes No Unsure 
Reason for unsure 
margins 
 
Histological 
margin 
involvement 
Ectocervical Endo Cervical Both 
Histology of LLETZ 
Biopsy 
CIN I CIN II CIN III/Ca-in situ 
Patient follow up Yes No 
Grade of CIN on 
Follow up Pap 
smear 
Clear ASCUS LGSIL HGSIL 
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